STEPHANIE BISCAY: Open Payments
NPI 1942382130 · PALM COAST, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$926 in 43 payments from 11 companies in 2025. Trend: 2023 $24 · 2024 $46 · 2025 $926
Food & beverage: $926
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $291 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $118 |
| Madrigal Pharmaceuticals | 4 | $111 |
| Regeneron Healthcare Solutions, Inc. | 5 | $98 |
| Aimmune Therapeutics, Inc. | 3 | $68 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $66 |
| GENZYME CORPORATION | 3 | $65 |
| Janssen Biotech, Inc. | 3 | $57 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Braintree Laboratories, Inc. | 1 | $14 |
Products named: DUPIXENT, LINZESS, REZDIFFRA, ENTYVIO, RINVOQ, SKYRIZI, ZENPEP, XIFAXAN.
Industry payments across FL — which companies pay providers there.
